"The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work".
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Adalimumab; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REWARD
- 10 Jun 2017 Biomarkers information updated
- 28 Jul 2011 Additional lead trial centers ans investigators identified as reported by ClinicalTrials.gov.
- 28 Jul 2011 Planned end date changed from 13 Aug 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov..